News | July 01, 2022
JB Pharma acquires 4 paediatric brands from Dr Reddy’s Laboratories
The total covered market size of four brands – Z&D, Pediclory, Pecef & Ezinapi combined is Rs 1800 crores
The total covered market size of four brands – Z&D, Pediclory, Pecef & Ezinapi combined is Rs 1800 crores
JB, in its new avatar, emerges as the fastest growing pharmaceuticals company in India
Ranked 25th with an impressive growth rate of 29% among Indian pharma companies in FY 2021-22
Under this initiative, 700 meals will be provided every day to four hospitals in Mumbai
The brand Azmarda fits well with JBCPL's overall strategy of strengthening its presence in the cardiology segment in India.
Leading brands like Sporlac, Lobun, Oxalo, Pubergen, Nano-leo and Gynogen will now be part of the JBCPL franchise
JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6
It will be marketed under the brand name Molunamax
The company plans to submit the IND application by the end of 2021
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
Subscribe To Our Newsletter & Stay Updated
